These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38105007)

  • 1. Lack of information on gender differences in the package inserts of prescription drugs in Japan.
    Maida N; Kondo S; Ogawa M; Hayashi N; Iwata H; Kobayashi N; Yamaura K
    Drug Discov Ther; 2024 Jan; 17(6):396-403. PubMed ID: 38105007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
    Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ontological Organization and Bioinformatic Analysis of Adverse Drug Reactions From Package Inserts: Development and Usability Study.
    Li X; Lin X; Ren H; Guo J
    J Med Internet Res; 2020 Jul; 22(7):e20443. PubMed ID: 32706718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan.
    Mino Y; Naito T; Ohshiro J; Yamada T; Kawakami J
    Pharm Pract (Granada); 2022; 20(4):2733. PubMed ID: 36793916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
    Tamura N; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of pharmacokinetic data provided in Japanese package inserts and interview forms focusing on urinary excretion of pharmacologically active species.
    Ohno Y; Kusama M; Hisaka A; Yanagihara Y; Suzuki H
    Yakugaku Zasshi; 2006 Jul; 126(7):489-94. PubMed ID: 16819270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
    Suzuki A; Sato H; Sasaki Y
    Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A 30-year history of the change in package insert for Japanese pharmaceutical medicines].
    Sasaki K; Kondo T
    Yakushigaku Zasshi; 2004; 39(2):276-85. PubMed ID: 16025649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Issues on package inserts of percutaneous tracheostomy kits].
    Mori M; Noguchi T
    Masui; 2007 Sep; 56(9):1104-10. PubMed ID: 17877059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Dosing Period in Package Inserts of Antimicrobial Agents Between Japan and the United States.
    Nishigaki T; Kato H; Sakamoto Y; Suzuki T; Kaneko M; Ide K; Okamura N; Suzuki T; Koike H; Sahashi Y
    Cureus; 2023 Apr; 15(4):e38266. PubMed ID: 37122972
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical information in drug package inserts in India.
    Shivkar YM
    J Postgrad Med; 2009; 55(2):104-7. PubMed ID: 19550054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
    Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
    Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
    Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the Safety of Perinatal Medication].
    Obara T
    Yakugaku Zasshi; 2021; 141(4):463-471. PubMed ID: 33790112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survey of Description on Package Inserts of OTC Drugs].
    Shimauchi A; Naganuma M; Sasaoka S; Hatahira H; Motooka Y; Hasegawa S; Fukuda A; Nakao S; Sakai C; Yokoyama S; Ino Y; Nakamura M; Iguchi K
    Yakugaku Zasshi; 2018; 138(2):259-267. PubMed ID: 29386439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of German package inserts.
    Fuchs J; Hippius M; Schaefer M
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):8-13. PubMed ID: 16425965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological gender-specific medicine].
    Ueno K; Negishi E
    Rinsho Byori; 2006 Jan; 54(1):51-8. PubMed ID: 16499230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug package inserts--varying information for the same medicines].
    Storflor JG; Pettersen LC; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2013 May; 133(9):955-9. PubMed ID: 23652143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.